 Efficacy safety low-dose aztreonam treatment moderate severe infections due gram-negative bacilli fifty-three patients moderate severe infections due gram-negative bacilli septicemia cases respiratory tract infection cases intraabdominal infection cases urinary tract infection cases aztreonam dosage usual Criteria inclusion study documented infection due gram-negative bacilli measurement severity disease Simplified Acute Physiology Score cases community-acquired infection Other aztreonam antibiotic active gram-negative bacilli treatment patients gram-positive anaerobic organisms additional agents effective organisms forty-one patients mean duration treatment days None gram-negative bacilli resistant Colonization gram-positive organism patients superinfection Aztreonam study dosage daily aztreonam appropriate treatment moderate severe infections due susceptible gram-negative bacilli